Sex Cord Gonadal Stromal Tumor Market Analysis Devices, By Top Key Players, Global Industry Size, Growth Opportunity, Latest Trends and Advanced Technologies To 2023

-

Market Highlights
The sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal component of the ovary and testis. This tumor comprises granulosa, thecal cells, and fibrocytes. Sex cord-gonadal stromal tumors are mostly of seven types, namely, granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, gynandroblastoma, Sex Cord Tumor with Annular Tubules (SCTAT), and Sertoli Leydig cell tumor. In humans, this type of tumor accounts for 8% of the ovarian cancers and around 5% of testicular cancers.

It is noted that the increasing cases of ovarian and testicular cancer, technological advancements, and increasing healthcare expenditure are the key factors driving the sex cord gonadal stromal tumor market.

 Various other factors such as the growing awareness about the cord-gonadal stromal tumor, unmet medical needs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the global sex cord-gonadal stromal tumor market.
Owing to the increasing cases of ovarian and testicular cancer, technological advancements, increasing healthcare expenditure, growing awareness about sex cord-gonadal stromal tumor, unmet medical needs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement, the sex cord-gonadal stromal tumor market has evolved significantly.

However, huge capital investments with low-profit margins, strict FDA regulations, and poor healthcare system in low and middle-income countries are likely to hamper the growth of the sex cord-gonadal stromal tumor market over the forecast period.

It is estimated that the sex cord-gonadal stromal tumor market is expected to grow at a CAGR of 6.5% during the forecast period of 2017-2023.

Key Players

Some of the key players in the global sex cord-gonadal stromal tumor market are Abbott, Abcam plc, Affymetrix, Inc., Agilent Technologies, Inc., Beckman, Dickinson and Company (BD), Bio SB Inc., BioCurex, BioModa, Inc., Bio-Rad Laboratories, Inc., Boston Scientific Corporation, Cell Signaling Technology, Inc., Clarient, Inc., CooperSurgical Inc., Correlogic Systems, Inc., Danaher Corporation, Epigenomics AG, F. Hoffmann-La Roche AG, Gen-Probe, Inc., Hologic, Inc., Johnson & Johnson Services, Inc., Karl Storz GmbH & Co. Kg, LiNA Medical USA, Merck Millipore, PerkinElmer, Inc., Qiagen, Radient Pharmaceuticals, Thermo Fisher Scientific Inc., Veridex LLC, and others.

Regional Analysis

The Americas dominates the sex cord-gonadal stromal tumor market owing to the increasing prevalence of ovarian cancer in this region and high healthcare expenditure. According to the American Cancer Society, around 22,240 women are likely to be diagnosed with ovarian cancer, and 14,070 women are likely to die from ovarian cancer, in 2018.

Europe holds the second position in the sex cord-gonadal stromal tumor market. The financial support provided by the government towards R&D and technological advancements are expected to drive the European sex cord-gonadal stromal tumor market. The increasing healthcare expenditure is also boosting the European sex cord-gonadal stromal tumor market.

According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014, i.e., EUR 321 billion which is further followed by France with EUR 237 billion and United Kingdom with EUR 223 billion. In 2016, the R&D expenditure in the pharmaceutical industry was EUR 35000 million, suggested by the European Federation of Pharmaceutical Industries and Association.

Asia Pacific is the fastest growing sex cord-gonadal stromal tumor market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015-2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014-2015.

The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.

Segmentation

The global sex cord-gonadal stromal tumor market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of tumor type, the sex cord-gonadal stromal tumor market is classified as granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, Sertoli Leydig cell tumor, gynandroblastoma, and Sex Cord Tumor with Annular Tubules (SCTAT). The granulosa cell tumor is further classified as functioning tumors and non-functioning tumors.

On the basis of diagnosis, the sex cord-gonadal stromal tumor market is classified as microscopy immunohistochemistry, tumor marker, ultrasound, Magnetic Resonance Imaging (MRI), and others. The tumor marker segment is further classified as inhibin-alpha, calretinin, Melan-A, and others.

On the basis of treatment, the sex cord-gonadal stromal tumor market is classified as chemotherapy, radiotherapy, surgery, and others. The surgery segment is further classified as salpingo-oophorectomy, abdominal hysterectomy, Retroperitoneal Lymph Node Dissection (RPLND), and radical inguinal orchiectomy. The sub-segment of salpingo-oophorectomy includes unilateral salpingo-oophorectomy and bilateral salpingo-oophorectomy.

On the basis of end-user, the sex cord-gonadal stromal tumor market is segmented into hospitals and clinics, cancer research centers, research and academic institutes, and others.

Get full report @https://www.marketresearchfuture.com/reports/sex-cord-gonadal-stromal-tumor-market-5912

Intended Audience

Medical Device Companies
Research and Development (R&D) Companies
Diagnostic Laboratories
Government Research Institutes
Academic Institutes and Universities

Browse other healthcare related report

Sex Cord Gonadal Stromal Tumor Market
Endometrial Cancer Market 

About Market Research Future:

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
https://www.marketresearchfuture.com


Comments

Post a Comment

Popular posts from this blog

Digital Genome Market Share 2020, Size, top companies, status 2027

-
  The research study presented here is an intelligent take on the Digital Genome Market Share by MRFR that explains important aspects such as competition, segmentation, and regional growth in great detail Digital genome is the study of DNA and other genetic information in plants and animals. It is used to discern the nature of chronic diseases and their ability to cure them in the coming years. The global digital genome market report by Market Research Future (MRFR) takes a look at the challenges and opportunities for the industry for the period of 2018 to 2027 (forecast period). The impact of the COVID-19 pandemic and its effects are explored in great detail. Also Read  https://www.abnewswire.com/pressreleases/digital-genome-market-outlook-2020-key-findings-regional-analysis-covid19-effect-key-players-profiles-future-prospects-and-forecast-to-2027_500552.html Digital Genome Market Scope The global  digital genome market  is expected to accrue major revenue...
Read more

Lymphedema Diagnostics Market Size, Growth Analysis and Technology Enhancements Briefing 2020 To 2023

-
  global lymphedema diagnostics market is expected to register a CAGR of ~7.1% during the forecast period of 2019 to 2025 and was valued at USD 22.6 million in 2018. Lymphatic obstruction or lymphedema is a long-term condition where the excess fluid forms in the body tissue and causes swelling commonly called edema. It develops due to the damaged lymphatic system. Sometimes it also develops after the treatment of breast cancer. Avail a Free sample@ https://www.marketresearchfuture.com/sample_request/8761 Segmentation The global lymphedema diagnostics market has been segmented based on type, technology, disease type, and end user. The market, based on type, has been divided into primary and secondary. The secondary lymphedema is likely to hold maximum market share in the global lymphedema diagnostics market owing to the large population related to the secondary lymphedema presence across the globe. The global lymphedema diagnostics market based on technology has been segregated int...
Read more

Parry-Romberg Syndrome Market 2019 size, share, Analysis, Growth, Guidelines, Overview, Upcoming Trends and Forecast to 2023

-
Image
According to the National Organization for Rare Disorder, Parry-Romberg syndrome is a rare and acquired disorder, which slowly shrink the skin and tissues of half of the face in most of the cases. In rare cases, both sides of the face are affected. In some cases, it may also affect the limbs usually on the same side of the body. The global Parry-Romberg syndrome market is expected grow at a steady CAGR of 7.8% during the forecasted period. The global Parry-Romberg syndrome market is majorly driven by the increasing skin diseases patient population, increasing prevalence neurological disorders, and rapidly increasing demand for better diagnosis & treatment methods. Key players of the market: ·          DePuy Synthes (U.S.) ·          Johnson & Johnson Services, Inc. (US) ·          Medtronic (Ireland, ·     ...
Read more